DEA To Stop Opioid Sales
DEA Given Go-Ahead to Prevent Drug Maker from Selling Opioids
August 21, 2017
The D.C. Circuit Court has lifted a stay that had prevented drugmaker Masters Pharmaceutical from selling controlled substances, including opioid medications. At the same time, the Drug Enforcement Administration (DEA) issued a challenge to Masters’ putative compliance with federal controlled-substance standards.
Masters’ drug-selling certificate was first revoked in 2008 on suspicion that the company was not acting to adequately prevent its drugs from being diverted into illegal channels. Masters was then ordered to spend $500,000 to establish a compliance program.
The company came under suspicion again in 2013, when the DEA alleged that Masters had provided millions of doses of the powerful opioid oxycodone to eight illegitimate pharmacies. Masters was found to be out of compliance, but was granted a stay. That stay has now been revoked, giving the DEA full authority to shut down Masters’ drug distribution operations.
The D.C. Circuit Court refused to hear Masters’ appeal.
The abuse of opioid painkillers claims the lives of some 30,000 Americans every year.
If you or a loved one has suffered from the horrors of opioid addiction, you may wish to seek a legal solution from the companies that may be responsible. TheLawFirm.com can help you – we’re experts in “bad drug” lawsuits. The consultation is free.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!